Skip to main content
. 2020 Apr 21;64(5):e02267-19. doi: 10.1128/AAC.02267-19

TABLE 11.

Dosing schedule with amorphous ribavirin-PRINT-CFI

Cohorta Dose in mg (no. of capsules) No. of participants (active/placebo)
A 7.5 (1) 6/2
B 15 (2) 6/2
C 30 (4) 6/2
Da 30 (4) 12/2
E 60 (8) 6/2
Fa 60 (8) 12/2
a

Cohorts D and F, which involved a BAL procedure, were dosed after assessing the tolerability of the 30- and 60-mg dose, respectively, in cohorts C and E.